AB-1002

Phase 2Small molecule

AAskBio Inc

AB-1002 is one of 26 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Heart FailurePhase 2

Active, not recruiting

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Monoferric

PPharmacosmos A/S

Preclinical

5 3

Zemplar

Savaysa

Xifaxan

2 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Coumadin

AAbbott

Preclinical

1 8

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 9

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Neo-Synephrine

EExela Pharma Sciences, LLC.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Active, not recruiting

Heart Failure

NCT05598333

Clinical

Trials by Indication[1]

Heart Failure1 trial

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

Active, not recruiting·AAskBio Inc·Phase 2·NCT05598333·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AB-1002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AB-1002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AB-1002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AskBio Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAskBio Inc

AB-1002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Heart Failure1 trial

References

Drug Info

Quick Facts

Related News